



HALF-YEARLY REPORT ON THE LIQUIDITY CONTRACT WITH GILBERT DUPONT

Paris, France, July 6, 2016

Pursuant to the liquidity contract entrusted to Gilbert Dupont, on 30 June 2016 the following assets appeared on the liquidity account:

- Number of shares: 30,282
- Cash balance of the liquidity account: €81,237.08

As a reminder, at the time of the last Half-Yearly report on 31 December 2015, the following resources were booked to the liquidity account:

- Number of shares: 36,363
- Cash balance of the liquidity account: €64,689.01

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies

Benoit Jacheet
CFO
investors@maunakeatech.com

United States

Zack Kubow / Lee Roth
The Ruth Group
646-536-7020 / 7012
zkubow@theruthgroup.com
lroth@theruthgroup.com

U.S. Media

Christopher Hippolyte
The Ruth Group
646-536-7023
chippolyte@theruthgroup.com

France and Europe

NewCap - Investor Relations
Florent Alba
+33 (0)1 44 71 94 94
maunakea@newcap.fr